tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Denali Therapeutics: Differentiated Hunter Syndrome Strategy and Non-Viral Platform Support Buy Rating and Long-Term Franchise Upside
PremiumRatingsDenali Therapeutics: Differentiated Hunter Syndrome Strategy and Non-Viral Platform Support Buy Rating and Long-Term Franchise Upside
1M ago
Denali Therapeutics: Strengthening LSD Clinical Profile and Attractive Risk‑Reward Support Buy Rating
Premium
Ratings
Denali Therapeutics: Strengthening LSD Clinical Profile and Attractive Risk‑Reward Support Buy Rating
1M ago
Denali Therapeutics price target raised to $40 from $32 at Morgan Stanley
Premium
The Fly
Denali Therapeutics price target raised to $40 from $32 at Morgan Stanley
2M ago
Denali Therapeutics price target lowered to $30 from $31 at Wedbush
PremiumThe FlyDenali Therapeutics price target lowered to $30 from $31 at Wedbush
3M ago
Denali Therapeutics Announces $200M Public Offering
Premium
Company Announcements
Denali Therapeutics Announces $200M Public Offering
3M ago
Denali Therapeutics 9.143M share Spot Secondary priced at $17.50
Premium
The Fly
Denali Therapeutics 9.143M share Spot Secondary priced at $17.50
3M ago
Denali Therapeutics price target raised to $31 from $30 at Wedbush
PremiumThe FlyDenali Therapeutics price target raised to $31 from $30 at Wedbush
4M ago
Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
Premium
Ratings
Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
4M ago
Denali Therapeutics: Promising Future with Strategic Agreements and Innovative Programs
Premium
Ratings
Denali Therapeutics: Promising Future with Strategic Agreements and Innovative Programs
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100